Amyloid and lipids in the pathology of Alzheimer disease

Amyloid

Volumn 6, Issue 2, 1999, Pages 136-145

  Roher, Alex E ^a   Kuo, Yu Min ^a   Kokjohn, Katrina M ^a   Emmerling, Mark R ^b   Gracon, Stephen ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

Alzheimer disease; Amyloid; Apolipoprotein E; Cholesterol; Lipids; Secretase

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; CARRIER PROTEIN; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; PRESENILIN 1; PRESENILIN 2; STEROL REGULATORY ELEMENT BINDING PROTEIN;

AGING; ALZHEIMER DISEASE; CELL LOSS; CHOLESTEROL BLOOD LEVEL; HUMAN; LIPID METABOLISM; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PAIRED HELICAL FILAMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REVIEW; SYNAPSE;

EID: 0032773427     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129909007315     Document Type: Review

References (130)

1. 1 Roher AE, Palmer KC, Yurewicz EC, Ball MJ and Greenberg BD (1993). Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem 61, 1916-1926
2. 2 Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E and Ball MJ (1993). β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 90, 10836-10840
3. 3 Hardy J (1997). Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20, 154-159
4. 4 Selkoe DJ (1994). Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 17, 489-517
5. 5 Pike CJ, Burdick D, Walencewicz AJ, Glabe CG and Cotman CW (1993). Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13, 1676-1687
6. 6 Pike CJ, Walencewicz AJ, Glabe CG and Cotman CW (1991). In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563, 311-314
7. 7 Terzi E, Holzemann G and Seelig J (1997). Interaction of Alzheimer β-amyloid peptide(1-40) with lipid membranes. Biochemistry 36, 14845-14852
8. 8 Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D and McGeer P (1996). Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17, 681-686
9. 9 Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA and Katzman R (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580
10. 10 Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, Checler F, Sisodia SS, Greengard P and Xu H (1999). Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides. Proc Natl Acad Sci USA 96, 742-747
11. 11 Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, Greengard P and Gandy S (1997). Generation of Alzheimer β-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci USA 94, 3748-3752
12. 12 Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ and Roher AE (1996). Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271, 4077-4081
13. 13 Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D and Schmidt AM (1996). RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691
14. 14 Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A and Stern D (1997). An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease. Nature 389, 689-695
15. 15 Paresce DM, Ghosh RN and Maxfield FR (1996). Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor. Neuron 17, 553-565
16. 16 El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC and Loike JD (1996). Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature 382, 716-719
17. 17 Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo YM and Roher AE (1996). Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 16, 6021-6037
18. 18 Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S and Price D (1995). Age-related CNS disorder and early death in transgenic FVB/ N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15, 1203-1218
19. 19 Higgins LS, Rodems JM, Catalano R, Quon D and Cordell B (1995). Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for β-APP751. Proc Natl Acad Sci USA 92, 4402-4406
20. 20 Nalbantoglu J, Tirado-Santiago G, Lahsaini A, Poirier J, Goncalves O, Verge G, Momoli F, Welner SA, Massicotte G, Julien JP and Shapiro ML (1997). Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387, 500-505
21. 21 LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC and Jay G (1995). The Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 9, 21-30
22. 22 LaFerla FM, Hall CK, Ngo L and Jay G (1996). Extracellular deposition of β-amyloid upon p53-dependent neuronal cell death in transgenic mice. J Clin Invest 98, 1626-1632
23. 23 Moran PM, Higgins LS, Cordell B and Moser PC (1995). Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proc Natl Acad Sci USA 92, 5341-5345
24. 24 Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F and Cole G (1996). Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102
25. 25 Masliah E, Sisk A, Mallory M, Mucke L, Schenk D and Games D (1996). Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J Neurosci 16, 5795-5811
26. 26 Braak H and Braak E (1997). Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18, 351-357
27. 27 Funato H, Yoshimura M, Kusui K, Tamaoka A, Ishikawa K, Ohkoshi N, Namekata K, Okeda R and Ihara Y (1998). Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am J Pathol 152, 1633-1640
28. 28 Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P and McConlogue L (1997). Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 94, 1550-1555
29. 29 Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T and Gillespie F (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527
30. 30 Weisgraber KH and Mahley RW (1996). Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 10, 1485-1494
31. 31 Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL and Pericak-Vance MA (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923
32. 32 Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P and Gauthier S (1993). Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342, 697-699
33. 33 Kurz A, Altland K, Lautenschlager N, Zimmer R, Busch R, Gerundt I, Lauter H and Muller U (1996). Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups. J Neurol 243, 452-456
34. 34 Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW and Breitner JC (1998). APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nat Genet 19, 321-322
35. 35 Pirttila T, Soininen H, Mehta PD, Heinonen O, Lehtimaki T, Bogdanovic N, Paljarvi L, Kim KS, Kosunen O, Winblad B, Riekkinen PS and Wisniewski HM (1997). Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Neurobiol Aging 18, 121-127
36. 36 Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B and Paul SM (1997). Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17, 263-264
37. 37 Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C and Mucke L (1997). Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease. Nature 389, 603-606
38. 38 Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, Frangione B, Ghiso J and Zlokovic BV (1997). Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β. J Neurochem 69, 1995-2004
39. 39 Koudinov AR, Koudinova NV, Kumar A, Beavis RC and Ghiso J (1996). Biochemical characterization of Alzheimer's soluble amyloid β protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 223, 592-597
40. 40 Permanne B, Perez C, Soto C, Frangione B and Wisniewski T (1997). Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240, 715-720
41. 41 Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T and Hyman BT (1995). Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38, 254-259
42. 42 Premkumar DR, Cohen DL, Hedera P, Friedland RP and Kalaria RN (1996). Apolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 148, 2083-2095
43. 43 Alonzo NC, Hyman BT, Rebeck GW and Greenberg SM (1998). Progression of cerebral amyloid angiopathy: accumulation of amyloid-β40 in affected vessels. J Neuropathol Exp Neurol 57, 353-359
44. 44 Ishii K, Tamaoka A, Mizusawa H, Shoji S, Ohtake T, Fraser PE, Takahashi H, Tsuji S, Gearing M, Mizutani T, Yamada S, Kato M, St.George-Hyslop PH, Mirra SS and Mori H (1997). Aβ1-40 but not Aβ1-42 levels in cortex correlate with apolipoprotein E ε4 allele dosage in sporadic Alzheimer's disease. Brain Res 748, 250-252
45. 45 Gearing M, Mori H and Mirra SS (1996). Aβ peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 39, 395-399
46. 46 Mann DM, Iwatsubo T, Pickering-Brown SM, Owen F, Saido TC and Perry RH (1997). Preferential deposition of amyloid β protein (Aβ) in the form Aβ40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E ε4 allele. Neurosci Lett 221, 81-84
47. 47 Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D and Roher AE (1998). Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem Biophys Res Commun 252, 711-715
48. 48 Lehtovirta M, Kuikka J, Helisalmi S, Hartikainen P, Mannerrnaa A, Ryynanen M, Riekkinen PS and Soininen H (1998). Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 64, 742-746
49. 49 Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, Lendon C, Han SW, Morris JC, Frank A, Vazquez J, Goate A and Valdivieso F (1998). A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 18, 69-71
50. 50 Holtzman DM, Pitas RE, Kilbridge J, Nathan B, Mahley RW, Bu G and Schwartz AL (1995). Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci USA 92, 9480-9484
51. 51 Kamboh MI, Ferrell RE and DeKosky ST (1998). Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene. Neurosci Lett 244, 65-68
52. 52 Fallin D, Kundtz A, Town T, Gauntlett AC, Duara R, Barker W, Crawford F and Mullan M (1997). No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample. Neurosci Lett 233, 145-147
53. 53 Clatworthy AE, Gomez-Isla T, Rebeck GW, Wallace RB and Hyman BT (1997). Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer disease. Arch Neurol 54, 1289-1292
54. 54 Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ and Katzman R (1997). Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 49, 56-61
55. 55 Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC and Goate AM (1997). Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci Lett 222, 187-190
56. 56 Csaszar A, Kalman J, Szalai C, Janka Z and Romics L (1997). Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease. Neurosci Lett 230, 151-154
57. 57 Fukagawa K, Knight DS, Hamilton KA and Tso P (1995). Immunoreactivity for apolipoprotein A-IV in tanycytes and astrocytes of rat brain. Neurosci Lett 199, 17-20
58. 58 Okumura T, Fukagawa K, Tso P, Taylor IL and Pappas TN (1996). Apolipoprotein A-IV acts in the brain to inhibit gastric emptying in the rat. Am J Physiol 270, G49-G53
59. 59 Giubilei F, D'Antona R, Antonini R, Lenzi GL, Ricci G and Fieschi C (1990). Serum lipoprotein pattern variations in dementia and ischemic stroke. Acta Neurol Scand 81, 84-86
60. 60 Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C and Larson EB (1995). Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45, 1092-1096
61. 61 Knebl J, DeFazio P, Clearfield MB, Little L, McConathy WJ, McPherson R and Lacko AG (1994). Plasma lipids and cholesterol esterification in Alzheimer's disease. Mech Ageing Dev 73, 69-77
62. 62 Liu Y, Peterson DA and Schubert D (1998). Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci USA 95, 13266-13271
63. 63 Grant W.B. (1997). Dietary links to Alzheimer's disease. Alz dis Rev 2, 42-55
64. 64 Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S and Breteler MB (1997). Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 153, 185-192
65. 65 Kalmijn S, Feskens EJ, Launer LJ and Kromhout D (1997). Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 145, 33-41
66. 66 Birge SJ (1997). The role of estrogen in the treatment of Alzheimer's disease. Neurology 48, S36-S41
67. 67 Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE and Hofman A (1997). Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28, 316-321
68. 68 Steinberg D (1997). Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272, 20963-20966
69. 69 Sugawa M, Ikeda S, Kushima Y, Takashima Y and Cynshi O (1997). Oxidized low density lipoprotein caused CNS neuron cell death. Brain Res 761, 165-172
70. 70 Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G and Cecchelli R (1997). A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 138, 877-889
71. 71 Wallin A, Gottfries CG, Karlsson I and Svennerholm L (1989). Decreased myelin lipids in Alzheimer's disease and vascular dementia. Acta Neurol Scand 80, 319-323
72. 72 Gottfries CG, Karlsson I and Svennerholm L (1996). Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int Psychogeriatr 8, 365-372
73. 73 Svennerholm L and Gottfries CG (1994). Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 62, 1039-1047
74. 74 Sparks DL, Scheff SW, Hunsaker JC, Liu H, Landers T and Gross DR (1994). Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126, 88-94
75. 75 Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N, Siman R, Greenberg BD, Scott RW and Flood DG (1998). Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol. J Biol Chem 273, 16576-16582
76. 76 Horiuchi K, Tajima S, Menju M and Yamamoto A (1989). Structure and expression of mouse apolipoprotein E gene. J Biochem (Tokyo) 106, 98-103
77. 77 Lee BR, Miller JM, Yang CY, Ramdas L, Yang ML, Morrisett JD and Mims MP (1991). Amino acid sequence of rabbit apolipoprotein E. J Lipid Res 32, 165-171
78. 78 Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D and Roses AD (1993). Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90, 9649-9653
79. 79 Davignon J, Gregg RE and Sing CF (1988). Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8, 1-21
80. 80 Cullen P, Cignarella A, Brennhausen B, Mohr S, Assmann G and von Eckardstein A (1998). Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J Clin Invest 101, 1670-1677
81. 81 Koudinov AR, Koudinova NV and Berezov TT (1996). Alzheimer's peptides Aβ 1-40 and Aβ 1-28 inhibit the plasma cholesterol esterification rate. Biochem Mol Biol Int 38, 747-752
82. 82 Bodovitz S and Klein WL ( 1996). Cholesterol modulates α-secretase cleavage of amyloid precursor protein. J Biol Chem 271, 4436-4440
83. 83 Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, Fumagalli R, Govoni S, Trabucchi M and Soma M (1997). Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 322, 893-898
84. 84 Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG and Simons K (1998). Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95, 6460-6464
85. 85 Mizuno T, Haass C, Michikawa M and Yanagisawa K (1998). Cholesterol-dependent generation of a unique amyloid β-protein from apically missorted amyloid precursor protein in MDCK cells. Biochim Biophys Acta 1373, 119-130
86. 86 Sakai J, Duncan EA, Rawson RB, Hua X, Brown MS and Goldstein JL (1996). Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 85, 1037-1046
87. 87 Hua X, Sakai J, Brown MS and Goldstein JL (1996). Regulated cleavage of sterol regulatory element binding proteins requires sequences on both sides of the endoplasmic reticulum membrane. J Biol Chem 271, 10379-10384
88. 88 Rawson RB, Zelenski NG, Nijhawan D, Ye J, Sakai J, Hasan MT, Chang TY, Brown MS and Goldstein JL (1997). Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. Mol Cell 1, 47-57
89. 89 Manni ME, Cescato R and Paganetti PA (1998). Lack of β-amyloid production in M19 cells deficient in site 2 processing of the sterol regulatory element binding proteins. FEBS Lett 427, 367-370
90. 90 Ross SL, Martin F, Simonet L, Jacobsen F, Deshpande R, Vassar R, Bennett B, Luo Y, Wooden S, Hu S, Citron M and Burgess TL (1998). Amyloid precursor protein processing in sterol regulatory element-binding protein site 2 protease-deficient Chinese hamster ovary cells. J Biol Chem 273, 15309-15312
91. 91 Tomita T, Chang TY, Kodama T and Iwatsubo T (1998). βAPP gamma-secretase and SREBP site 2 protease are two different enzymes. Neuroreport 9, 911-913
92. 92 Roth GS, Joseph JA and Mason RP (1995). Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci 18, 203-206
93. 93 Maruyama K, Kametani F, Usami M, Yamao-Harigaya W and Tanaka K (1991). "Secretase," Alzheimer amyloid protein precursor secreting enzyme is not sequence-specific. Biochem Biophys Res Commun 179, 1670-1676
94. 94 Sisodia SS (1992). β-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA 89, 6075-6079
95. 95 Komano H, Seeger M, Gandy S, Wang GT, Krafft GA and Fuller RS (1998). Involvement of cell surface glycosyl-phosphatidylinositol-linked aspartyl proteases in α-secretase-type cleavage and ectodomain solubilization of human Alzheimer β-amyloid precursor protein in yeast. J Biol Chem 273, 31648-31651
96. 96 Mason RP, Shoemaker WJ, Shajenko L and Herbette LG (1993). X-ray diffraction analysis of brain lipid membrane structure in Alzheimer's disease and β-amyloid peptide interactions. Ann N Y Acad Sci 695, 54-58
97. 97 Koudinova NV, Berezov TT and Koudinov AR (1996). Multiple inhibitory effects of Alzheimer's peptide Aβ1-40 on lipid biosynthesis in cultured human HepG2 cells. FEBS Lett 395, 204-206
98. 98 Liu Y, Peterson DA and Schubert D (1998). Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci USA 95, 13266-13271
99. 99 Choo-Smith LP, Garzon-Rodriguez W, Glabe CG and Surewicz WK (1997). Acceleration of amyloid fibril formation by specific binding of Aβ-(1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 272, 22987-22990
100. 100 Yanagisawa K and Ihara Y (1998). GM1 ganglioside-bound amyloid β-protein in Alzheimer's disease brain. Neurobiol Aging 19, S65-S67
101. 101 Tamaoka A, Endoh R, Shoji S, Takahashi H, Hirokawa K, Teplow DB, Selkoe DJ and Mori H (1996). Antibodies to amyloid β protein (Aβ) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Neurobiol Aging 17, 405-414
102. 102 Beffert U, Aumont N, Dea D, Lussier-Cacan S, Davignon J and Poirier J (1998). β-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons. J Neurochem 70, 1458-1466
103. 103 Urmoneit B, Prikulis I, Wihl G, D'Urso D, Frank R, Heeren J, Beisiegel U and Prior R (1997). Cerebrovascular smooth muscle cells internalize Alzheimer amyloid β protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest 77, 157-166
104. 104 Pillot T, Goethals M, Vanloo B, Talussot C, Brasseur R, Vandekerckhove J, Rosseneu M and Lins L (1996). Fusogenic properties of the C-terminal domain of the Alzheimer β-amyloid peptide. J Biol Chem 271, 28757-28765
105. 105 Pollard HB, Arispe N and Rojas E (1995). Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Cell Mol Neurobiol 15, 513-526
106. 106 Zubenko GS, Winwood E, Jacobs B, Teply I, Stiffler JS, Hughes HB, Huff FJ, Sunderland T and Martinez AJ (1999). Prospective study of risk factors for Alzheimer's disease: results at 7.5 years. Am J Psychiatry 156, 50-57
107. 107 Yan SD, Shi Y, Zhu A, Fu J, Zhu H, Zhu Y, Gibson L, Stern E, Collison K, Al-Mohanna F, Ogawa S, Roher A, Clarke SG and Stern DM (1999). Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Aβ-induced cytotoxicity. J Biol Chem 274, 2145-2156
108. 108 Zhuchenko O, Wehnert M, Bailey J, Sun ZS and Lee CC (1996). Isolation, mapping, and genomic structure of an X-linked gene for a subunit of human mitochondrial complex I. Genomics 37, 281-288
109. 109 Furuta S, Kobayashi A, Miyazawa S and Hashimoto T (1997). Cloning and expression of cDNA for a newly identified isozyme of bovine liver 3-hydroxyacyl-CoA dehydrogenase and its import into mitochondria. Biochim Biophys Acta 1350, 317-324
110. 110 Gray EG, Paula-Barbosa M and Roher A (1987). Alzheimer's disease: paired helical filaments and cytomembranes. Neuropathol Appl Neurobiol 13, 91-110
111. 111 Sparkman DR, Goux WJ, Jones CM, White CL and Hill SJ (1991). Alzheimer disease paired helical filament core structures contain glycolipid. Biochem Biophys Res Commun 181, 771-779
112. 112 Goux WJ, Rodriguez S and Sparkman DR (1995). Analysis of the core components of Alzheimer paired helical filaments. A gas chromatography/mass spectrometry characterization of fatty acids, carbohydrates and long-chain bases. FEBS Lett 366, 81-85
113. 113 Goux WJ, Rodriguez S and Sparkman DR (1996). Characterization of the glycolipid associated with Alzheimer paired helical filaments. J Neurochem 67, 723-733
114. 114 Wilson DM and Binder LI (1997). Free fatty acids stimulate the polymerization of tau and amyloid β peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am J Pathol 150, 2181-2195
115. 115 Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C and Grobbee DE (1997). Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349, 151-154
116. 116 Slooter AJ, Tang MX, Van Duijn CM, Stern Y, Ott A, Bell K, Breteler MM, Van Broeckhoven C, Tatemichi TK, Tycko B, Hofman A and Mayeux R (1997). Apolipoprotein E ε4 and the risk of dementia with stroke. A population-based investigation. JAMA 277, 818-821
117. 117 Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA and Markesbery WR (1997). Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277, 813-817
118. 118 Lovell MA, Ehmann WD, Mattson MP and Markesbery WR (1997). Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18, 457-461
119. 119 Montine KS, Olson SJ, Amarnath V, Whetsell WOJ, Graham DG and Montine TJ (1997). Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am J Pathol 150, 437-443
120. 120 Roberts GW, Gentleman SM, Lynch A and Graham DI (1991). βA4 amyloid protein deposition in brain after head trauma. Lancet 338, 1422-1423
121. 121 Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL and Markesbery WR (1990). Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 11, 601-607
122. 122 Soneira CF and Scott TM (1996). Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. Clin Anat 9, 118-127
123. 123 Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM and Hunsaker JC (1995). Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 131, 162-169
124. 124 Gabuzda D, Busciglio J, Chen LB, Matsudaira P and Yankner BA (1994). Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269, 13623-13628
125. 125 Jendroska K, Poewe W, Daniel SE, Pluess J, Iwerssen-Schmidt H, Paulsen J, Barthel S, Schelosky L, Cervos-Navarro J and DeArmond SJ (1995). Ischemic stress induces deposition of amyloid β immunoreactivity in human brain. Acta Neuropathol (Berl) 90, 461-466
126. 126 Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E, Ihara Y and Kawashima S (1994). Spatial resolution of the primary β-amyloidogenic process induced in postischemic hippocampus. J Biol Chem 269, 15253-15257
127. 127 Wisniewski HM and Maslinska D (1996). β-protein immunoreactivity in the human brain after cardiac arrest. Folia Neuropathol 34, 65-71
128. 128 Mattson MP, Fu W, Waeg G and Uchida K (1997). 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. Neuroreport 8, 2275-2281
129. 129 Nordberg A (1996). Application of PET in dementia disorders. Acta Neurol Scand Suppl 168, 71-76
130. 130 Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN and Osborne D (1996). Preclinical evidence of Alzheimer's disease in persons homozy-gous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334, 752-758